8周一次给药,为成人和1月龄及以上儿童PNH患者带来长效治疗选择 上海2026年8月20日 /美通社/ -- 阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞®(英文商品名:Ultomiris®,通用名:瑞利珠单抗注射液),已获得中国国家药品监督管理局(NMPA)批准,用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症(PNH)患者的治疗。 此次获批是基于三项全球III期(ALXN1210-PNH...
Source Link8周一次给药,为成人和1月龄及以上儿童PNH患者带来长效治疗选择 上海2026年8月20日 /美通社/ -- 阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞®(英文商品名:Ultomiris®,通用名:瑞利珠单抗注射液),已获得中国国家药品监督管理局(NMPA)批准,用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症(PNH)患者的治疗。 此次获批是基于三项全球III期(ALXN1210-PNH...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.